IASLC Molecular Guideline Testing: What’s Changing?

Published on

Topics include: Understanding

With new lung cancer driver mutations being discovered, will molecular testing guidelines cover them also? Meet Dr. Paul Bunn of the University of Colorado.  Dr. Bunn has dedicated his entire career to researching novel therapies for lung cancer patients.  Having recently returned from the 17th Annual IASLC Targeted Therapy Meeting, Dr. Bunn shares his insights into the latest changes in molecular testing guidelines.

Produced by Patient Power and Antidote in association with the Precision Medicine for Me Initiative.

View more programs featuring

Related Programs

Is Precision Medicine the Future of Cancer Treatment?

Precision Medicine is the future. Each patient is different, and each patient’s treatment will be based on your unique “body print.”


Join Our Community Register for Events Read Our Latest Blog

Page last updated on April 18, 2017